文献速递眼底病与葡萄膜炎

雷珠单抗治疗单眼/双眼新生血管性年龄相关性黄斑变性的安全性与耐受性:12个月TWEYEs研究

Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study.
PubMed 文献 · Br J Ophthalmol · 2019-05-11

这项为期12个月的前瞻性、多中心、开放标签、单臂、实用性干预研究纳入941例年龄≥50岁的单眼/双眼新生血管性年龄相关性黄斑变性患者,按获批标签接受雷珠单抗0.5 mg治疗。结果显示系统性药物相关不良事件和特别关注不良事件发生率低,单眼/双眼治疗患者均表现出良好的安全性和耐受性。

要点

  • 研究纳入941例单眼/双眼新生血管性年龄相关性黄斑变性患者,936例至少接受一次雷珠单抗治疗。
  • 单眼治疗患者平均注射5.4次,双眼治疗患者平均注射10.6次。
  • 系统性药物相关不良事件3例(均为严重,均发生于单眼治疗患者),系统性特别关注不良事件18例。

核心结论

  • 在真实世界环境中,雷珠单抗用于单眼/双眼治疗的新生血管性年龄相关性黄斑变性患者表现出良好的安全性和耐受性,不良事件和特别关注不良事件发生率低。

研究设计与样本

  • 12个月、前瞻性、多中心、开放标签、单臂、实用性干预研究,纳入941例年龄≥50岁的单眼/双眼新生血管性年龄相关性黄斑变性且最佳矫正视力<2/10和/或第二眼受累(不论视力)的患者。
  • 雷珠单抗按获批标签给药,每月注射直至达到最大稳定视力(初始可能需要三次或以上注射),之后每月监测视力,若因疾病活动导致视力下降则恢复治疗。

主要发现

  • 936例至少接受一次雷珠单抗治疗的患者中,823例单眼治疗、113例双眼(非同时)治疗。
  • 研究期间单眼治疗患者平均(标准差)注射5.4(2.9)次,双眼治疗患者平均(标准差)注射10.6(5.0)次。
  • 发生3例系统性药物相关不良事件(均为严重,均发生于单眼治疗患者)和18例系统性特别关注不良事件(11例严重,单眼/双眼治疗分别为16例/2例)。
  • 考虑15天/30天风险期,单眼治疗患者系统性药物相关不良事件的年发病率(事件/1000人年)为11.0/8.5;同样风险期下,单眼治疗患者系统性特别关注不良事件的年发病率为22.1/19.9。
  • 考虑30天风险期,眼部药物相关不良事件的年发病率(事件/1000治疗眼年)为23,特别关注不良事件为11.5。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the safety and tolerability of ranibizumab 0.5 mg in patients with uni/bilateral neovascular age-related macular degeneration (nAMD) and best-corrected visual acuity (BCVA)<2/10 and/or second eye affected, regardless of BCVA. METHODS: In this 12-month, prospective, multicentre, open-label, single arm, pragmatic interventional study, patients (N=941) aged ≥ 50 years were to receive ranibizumab as per approved label, monthly until maximum stable visual acuity (VA) was achieved (initially, three or more injections may be required). Thereafter, patients were to be monitored monthly for VA and treatment was to be resumed if VA was reduced due to disease activity. RESULTS: Of the 936 patients treated with ranibizumab at least once during the study, 823/113 were unilaterally/bilaterally (not simultaneously) treated . The mean (SD) number of ranibizumab injections during the study was 5.4 (2.9)/10.6 (5.0) injections in uni/bilaterally treated patients. Three systemic drug-related adverse events (AEs) (all serious, all in unilaterally treated patients) and 18 systemic AE of special interest (AESIs) (11 serious, 16/2 in unilaterally/bilaterally treated patients) occurred during the study. The annual incidence rate (AIR) (events/1000 person-years) for systemic drug-related AEs, considering a 15-day/30-day risk period, 11.0/8.5 for unilaterally treated patients. Considering the same risk period, the AIR (events/1000 person-years) for systemic AESIs for unilaterally treated patients was 22.1/19.9. Considering a 30-day risk period, the AIR (events/1000 treated eye-years) of ocular drug-related AEs was 23 and AESIs was 11.5. CONCLUSIONS: The low incidence of AEs and AESIs demonstrated the good safety and tolerability of ranibizumab in unilaterally/bilaterally treated patients with nAMD in this real-world setting.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bandello F, Staurenghi G, Ricci F, et al. Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study. Br J Ophthalmol. 2019. PMID: 31079057. doi:10.1136/bjophthalmol-2019-313907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。